As a leading non-IgG therapeutic antibodies provider in the world, Creative Biolabs has successfully completed a series of challenges in the past years. In particular, we have established an advanced non-IgG antibody (mainly IgA, IgM, and IgE)-based vaccine development platform which enables us to offer a series of high-quality services for our worldwide customers.
Brief Introduction to IgE Antibody Application
Immunoglobulin E (IgE) is an antibody which plays a significant role in regulating immune reaction against allergic diseases. The studies have revealed that the IgE-Fc domain can bind to Fc receptors (FcεRI and FcεRII/CD23) and then activate effector functions to trigger hypersensitivity response in mast cells or basophils. Thus, IgE-associated allergy is the most common immunologically-mediated hypersensitivity disease. Meanwhile, the power effector function of IgE has been proved to be useful in a wide variety of aspects, for example, it is related with the mammalian evolution and it can mediate the immune response against parasites or animal venoms. In addition, research has suggested that IgE can restrict tumor growth in a series of mice models by mediating allergic responses in vivo. It is demonstrated that IgE is a perfect candidate for developing a monoclonal antibody (mAb) or vaccines against a number of disease-associated targets.
Fig.1 The role of IgE in the context of IgE-mediated allergy. (Henrike, 2016)
The Application of IgE Antibody in Vaccine Development
At present, some researches have tried to use IgE as an effective adjuvant for anti-cancer vaccination, which based on the fact that activation of the antigen-IgE-FcεRI axis has a profound impact on the cellular coordination and programming of the immune system, leading to a strong inflammatory state. Mice immunized with IgE showed a strong protective effect against tumors, suggesting that the specific adjuvant effect of IgE has been established. On the contrary, non-immunized mice or immunized with IgG targeting cells showed the relatively rapid growth of tumors and death. Overall, the mechanism behind IgE-driven tumor vaccination appears to imply IgE-FcεRI recognition, in a tumor cell-FcεRI+ cell scenario. Therefore, the role of allergy mediated by IgE in malignant tumors may open up a new way for cancer treatment.
Creative Biolabs offers a number of IgE antibodies of different species to meet any requirement of vaccine development. Besides, we also provide a panel of non-IgG antibody-based vaccine development services, such as vaccine design, immunogenicity, and safety evaluation.
Fig.2 Schematics of the mechanisms behind IgE adjuvanticity in anti-tumor vaccination. (Jensen-Jarolim, 2008)
Aided by our rich experience and professional scientists, Creative Biolabs is dedicated to offering a series of antibody development solutions for worldwide customers. In addition to IgE, we also provide related and customized other non-IgG antibody services to meet every client’s specific requirements. For more information, please feel free to contact us or send us an inquiry.
References
- Henrike, C. H.; et al. IgE - the main player of food allergy. Drug Discov Today: Dis Model. 2016, 431: 8.
- Jensen-Jarolim, E.; et al. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy. 2008, 63(10): 1255-1266.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.
